Atomoxetine and circadian gene expression in human dermal fibroblasts from study participants with a diagnosis of attention-deficit hyperactivity disorder

Atomoxetine (ATO) is a second line medication for attention-deficit hyperactivity disorder (ADHD). We proposed that part of the therapeutic profile of ATO may be through circadian rhythm modulation. Thus, the aim of this study was to investigate the circadian gene expression in primary human-derived...

Descripción completa

Detalles Bibliográficos
Autores principales: Faltraco, Frank, Palm, Denise, Uzoni, Adriana, Simon, Frederick, Tucha, Oliver, Thome, Johannes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Vienna 2021
Materias:
Psychiatry and Preclinical Psychiatric Studies - Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8295110/
https://www.ncbi.nlm.nih.gov/pubmed/34273025
http://dx.doi.org/10.1007/s00702-021-02373-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8295110/
https://www.ncbi.nlm.nih.gov/pubmed/34273025
http://dx.doi.org/10.1007/s00702-021-02373-5

Ejemplares similares